Hunting for a pleural fluid test for mesothelioma: Is soluble mesothelin the answer?

Thorax

Volumn 62, Issue 7, 2007, Pages 561-562

  Lee, Y C Gary ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MESOTHELIN;

DIAGNOSTIC TEST; EDITORIAL; MESOTHELIOMA; PLEURA EFFUSION; PLEURA FLUID; PRIORITY JOURNAL; THORACOCENTESIS;

HUMANS; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; PLEURAL EFFUSION; TUMOR MARKERS, BIOLOGICAL;

EID: 34447296458     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2006.076612     Document Type: Editorial

References (19)

1. Light RW, Lee YCG. Textbook of pleural diseases. London: Arnold Press, 2003.
2. Lee YCG, Davies RJO, Light RW. Diagnosing pleural effusion: moving beyond transudate-exudate separation. Chest 2007;131:942-3.
3. Perez-Rodriguez E, Jimenez Castro D. The use of adenosine deaminase and adenosine deaminase isoenzymes in the diagnosis of tuberculous pleuritis. Curr Opin Pulm Med 2000;6:259-66.
4. West SD, Lee YCG. Current management of malignant pleural mesothelioma. Clin Chest Med 2006;27:335-54.
5. Scherpereel A, Lee YCG. Biomarkers for mesothelioma. Curr Opin Pulm Med 2007;13 (in press).
6. Kettunen E, Nicholson AG, Nagy B, et al. L1CAM, INP10, P-cadherin, tPA and ITGB4 over-expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray. Carcinogenesis 2005;26:17-25.
7. Gordon GJ. Transcriptional profiling of mesothelioma using microarrays. Lung Cancer 2005;49(Suppl 1):S99-103.
8. Robinson BWS, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-6.
9. Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;173:1155-60.
10. Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006;12:447-53.
11. Beyer HL, Geschwindt RD, Glover CL, et al. MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem 2007;53:666-72.
12. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004;10:3937-42.
13. Hellstrom I, Raycraft J, Kanan S, et al. Mesothelin variant I is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev 2006;15:1014-20.
14. Ho M, Onda M, Wang QC, et al. Mesothelin is shed from tumor cells. Cancer Epidemiol Biomarkers Prev 2006;15:1751.
15. Creaney J, Yeoman D, Naumoff LK, et al. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 2007;62:569-76.
16. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005;294:66-70.
17. Goldberg EM, Simunovic LM, Drake SL, et al. Comparison of serum CA 19-9 and CEA levels in a population at high risk for colorectal cancer. Hybridoma 1989;8:569-75.
18. Helzlsouer KJ, Bush TL, Alberg AJ, et al. Prospective study of serum CA-125 levels as markers of ovarian cancer. JAMA 1993;269:1123-6.
19. Ordonez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003;16:192-7.